Raed Alalawi, MD
Pulmonary Disease · Lubbock, TXNPI 1366566176
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (27.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 31 manufacturers reported payments, led by Pulmonx Corporation at 40.3% of the total. Reporting peaked in 2019 at $12,947 and has fallen 79.0% since, to $2,720 in 2025. Among pulmonary disease clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 228 payments — averaging $180.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pulmonx Corporation$17K
- Intuitive Surgical$8K
- Cook Incorporated$5K
- Pinnacle Biologics, Inc$4K
- CSA Medical, Inc$3K
- Veran Medical Technologies, Inc.$967
- plus $4K from 25 others
Across 38 payments — averaging $3909.11 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pulmonx Corporation$81K
- Veran Medical Technologies, Inc.$49K
- Merck$18K
What the payments were for
- Consulting fees$11,38028%
- Speaking & faculty fees$9,20022%
- Travel & lodging$9,01422%
- Food & beverage$8,56721%
- Education$3,0327%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pulmonx Corporation | 55 | $16,607 |
| Intuitive Surgical | 41 | $8,210 |
| Cook Incorporated | 1 | $5,400 |
| Pinnacle Biologics, Inc | 20 | $3,859 |
| CSA Medical, Inc | 2 | $2,644 |
| Veran Medical Technologies, Inc. | 6 | $967 |
| Olympus America Inc. | 25 | $617 |
| Inari Medical, Inc. | 3 | $555 |
| Johnson & Johnson(2 entities) | 11 | $539 |
| United Therapeutics Corporation | 4 | $347 |
| Grifols USA, LLC | 6 | $226 |
| Actelion Pharmaceuticals US, Inc. | 3 | $178 |
| GSK | 11 | $164 |
| Philips North America LLC | 6 | $131 |
| Galvanize Therapeutics, Inc | 1 | $98 |
| Cook Medical LLC | 2 | $91 |
| AbbVie(2 entities) | 4 | $90 |
| Boehringer Ingelheim | 3 | $67 |
| AstraZeneca | 4 | $66 |
| Sandoz | 4 | $56 |
| Insmed, Inc. | 3 | $54 |
| Electromed, Inc. | 4 | $44 |
| Boston Scientific | 1 | $32 |
| Regeneron Healthcare Solutions, Inc. | 1 | $31 |
| Vapotherm Inc | 1 | $28 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $20 |
| Paratek Pharmaceuticals, Inc. | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $15 |
| Mylan Specialty L.p. | 1 | $13 |
| Bayer | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CHARTIS CATHETER$8,041
- ZEPHYR DELIVERY CATHETER$8,041
- ZEPHYR ENDOBRONCHIAL VALVE$8,041
- PULMONX CHARTIS TABLET CONSOLE$8,041
- Pulmonx Endobronchial Valve EBV$7,485
- Blue Rhino$5,400
- Da Vinci Surgical System$3,876
- Photofrin$3,306
- ION$3,000
- Spin$890
- FLOWTRIEVER CATHETER, S$555
- CT THROMBECTOMY SYSTEM KIT$555
- MONARCH$247
- Prolastin-C$148
- Spiration Valve System$135
- OPSUMIT$124
- UPTRAVI$124
- REMODULIN$124
- ORENITRAM$124
- EVIS EXERA II ULTRASONIC BRONCHOFIBERVIDEOSCOPE$115
How this compares
$41,194 in reported general payments places this provider in the 90th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Aralast NpAlpha-1-Proteinase Inhibitor | 13 | $144,041 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $23,262 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $7,767 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 20 | $472 |
| Azithromycin | 33 | $155 |
| Prednisone | 20 | $64 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaBreztri Aerosphere | $66 | $23,26217 claims |
| GSKTrelegy Ellipta | $164 | $7,76712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Lubbock
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
- Jefy MathewThe Woodlands$318K
- Rodolfo Estrada AnzuetoSan Antonio$300K
- Zeenat SafdarHouston$291K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.